Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

Core Insights - Metsera, Inc. is set to present clinical and preclinical data on its next-generation therapies for obesity and metabolic diseases at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) from September 15-19, 2025 in Vienna, Austria [1][2] Company Overview - Metsera is a clinical-stage biopharmaceutical company focused on developing innovative medicines for obesity and metabolic diseases, founded in 2022 and based in New York City [4] - The company is advancing a diverse portfolio of oral and injectable therapies, including incretin and non-incretin options, aimed at addressing multiple therapeutic targets in the evolving weight loss treatment landscape [4] Clinical and Preclinical Presentations - The company will present a late-breaking oral presentation on the pharmacokinetics, weight loss, and tolerability of its ultra-long acting amylin analog MET-233i on September 17, 2025 [3] - Two preclinical presentations will focus on the combination of MET-233i with MET-097i, an ultra-long acting GLP-1 receptor agonist, showcasing significant weight loss in preclinical studies [2][3]